首页 > 最新文献

Multidisciplinary Respiratory Medicine最新文献

英文 中文
Do gene-environment interactions play a role in COVID-19 distribution? The case of Alpha-1 Antitrypsin, air pollution and COVID-19. 基因-环境相互作用是否在COVID-19传播中发挥作用?α -1抗胰蛋白酶病例、空气污染与COVID-19
IF 2.3 Pub Date : 2021-04-22 eCollection Date: 2021-01-15 DOI: 10.4081/mrm.2021.741
Nicola Murgia, Angelo Guido Corsico, Gennaro D'Amato, Cara Nichole Maesano, Arturo Tozzi, Isabella Annesi-Maesano

Background: Gene-environment interactions are relevant for several respiratory diseases. This communication raises the hypothesis that the severity of COVID-19, a complex disease where the individual response to the infection may play a significant role, could partly result from a gene-environment interaction between air-pollution and Alpha-1 Antitrypsin (AAT) genes.

Methods: To evaluate the impact of the AAT and air pollution interaction on COVID-19, we introduced an AAT*air pollution global risk score summing together, in each country, an air pollution score (ozone, nitrogen dioxide and fine particulate matter) and an AAT score (which sums the ranked frequency of MZ, SZ, MS). We compared this global score with the ranking of European countries in terms of death number per million persons.

Results: The ranking of the AAT*air pollution global risk score matched the ranking of the countries in terms of the observed COVID-19 deaths per 1M inhabitants, namely in the case of the first European countries: Belgium, UK, Spain, Italy, Sweden, France. We observed parallelism between the number of COVID deaths and the AAT*air pollution global risk in Europe. AAT anti-protease, immune-modulating and coagulation-modulating activities may explain this finding, although very speculatively.

Conclusions: Even if further studies taking into account genetic background, population density, temporal dynamics of individual epidemics, access to healthcare, social disparities and immunological response to SARS-CoV2 are needed, our preliminary observation urges to open a discussion on gene-environment interactions in COVID-19.

背景:基因-环境相互作用与几种呼吸系统疾病有关。这种交流提出了一种假设,即COVID-19的严重程度可能部分源于空气污染和α -1抗胰蛋白酶(AAT)基因之间的基因-环境相互作用。COVID-19是一种复杂的疾病,个体对感染的反应可能发挥重要作用。方法:为了评估AAT和空气污染相互作用对COVID-19的影响,我们引入了AAT*空气污染全球风险评分,将每个国家的空气污染评分(臭氧、二氧化氮和细颗粒物)和AAT评分(MZ、SZ、MS的排名频率)相加。我们将这一全球得分与欧洲国家每百万人死亡人数的排名进行了比较。结果:AAT*空气污染全球风险评分的排名与观察到的每100万居民COVID-19死亡人数的国家排名相符,即欧洲国家:比利时、英国、西班牙、意大利、瑞典、法国。我们观察到欧洲新冠肺炎死亡人数与AAT*空气污染全球风险之间存在平行关系。AAT的抗蛋白酶、免疫调节和凝血调节活性可以解释这一发现,尽管这只是推测性的。结论:即使需要进一步研究考虑遗传背景、人口密度、个体流行病的时间动态、医疗保健可及性、社会差异和对SARS-CoV2的免疫反应,我们的初步观察也促使人们对COVID-19的基因-环境相互作用展开讨论。
{"title":"Do gene-environment interactions play a role in COVID-19 distribution? The case of Alpha-1 Antitrypsin, air pollution and COVID-19.","authors":"Nicola Murgia,&nbsp;Angelo Guido Corsico,&nbsp;Gennaro D'Amato,&nbsp;Cara Nichole Maesano,&nbsp;Arturo Tozzi,&nbsp;Isabella Annesi-Maesano","doi":"10.4081/mrm.2021.741","DOIUrl":"https://doi.org/10.4081/mrm.2021.741","url":null,"abstract":"<p><strong>Background: </strong>Gene-environment interactions are relevant for several respiratory diseases. This communication raises the hypothesis that the severity of COVID-19, a complex disease where the individual response to the infection may play a significant role, could partly result from a gene-environment interaction between air-pollution and Alpha-1 Antitrypsin (AAT) genes.</p><p><strong>Methods: </strong>To evaluate the impact of the AAT and air pollution interaction on COVID-19, we introduced an AAT*air pollution global risk score summing together, in each country, an air pollution score (ozone, nitrogen dioxide and fine particulate matter) and an AAT score (which sums the ranked frequency of MZ, SZ, MS). We compared this global score with the ranking of European countries in terms of death number per million persons.</p><p><strong>Results: </strong>The ranking of the AAT*air pollution global risk score matched the ranking of the countries in terms of the observed COVID-19 deaths per 1M inhabitants, namely in the case of the first European countries: Belgium, UK, Spain, Italy, Sweden, France. We observed parallelism between the number of COVID deaths and the AAT*air pollution global risk in Europe. AAT anti-protease, immune-modulating and coagulation-modulating activities may explain this finding, although very speculatively.</p><p><strong>Conclusions: </strong>Even if further studies taking into account genetic background, population density, temporal dynamics of individual epidemics, access to healthcare, social disparities and immunological response to SARS-CoV2 are needed, our preliminary observation urges to open a discussion on gene-environment interactions in COVID-19.</p>","PeriodicalId":49031,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2021-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/84/f8/mrm-16-1-741.PMC8114100.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39000207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
The contribution of patients' lung function to the inspiratory airflow rate achievable through a DPIs' simulator reproducing different intrinsic resistance rates. 患者肺功能对吸气气流率的贡献通过dpi模拟器再现不同的固有阻力率。
IF 2.3 Pub Date : 2021-04-15 eCollection Date: 2021-01-15 DOI: 10.4081/mrm.2021.752
Roberto W Dal Negro, Paola Turco, Massimiliano Povero

Background: The performance of DPIs depends on several physiological (patient-dependent) and technological (device-dependent) factors. The inspiratory airflow rate is the only active force generated and operating in the system for inducing the required pressure drop and eliciting the resistance-induced turbulence needed to disaggregate the powder through the device. The present study aimed to investigate in the most prevalent respiratory disorders whether and at what extent the inspiratory airflow rate achievable when inhaling through a DPIs' simulator reproducing different intrinsic resistance regimens (low, mid, and high resistance) is affected by peculiar changes in lung function and/or can be predicted by any specific lung function parameter.

Methods: The inspiratory airflow rate was assessed in randomized order by the In-Check DIAL G16 at low, mid, and high resistance regimens in a sample of consecutive subjects at recruitment. Independent predictors of the probability to achieve the expected inhalation airflow rate were investigated by means of a multivariate logistic regression model, specific to the disease.

Results: A total of 114 subjects were recruited (asthmatics n=30; COPD n=50, restrictive patients n=16, and normal subjects n=18). The mean values of the expected inspiratory airflow rate achieved proved significantly different within the groups (p<0.0001), independently of sex and age. In asthmatics and in COPD patients, the mid-resistance regimen proved highly associated with the highest mean values of airflow rates obtained. Low- and high-resistance regimens were significantly less likely to consent to achieve the expected level of inspiratory airflow rate (OR<1 in all comparisons). Restrictive patients performed the lowest airflow rates at the low-resistance regimen (p<0.01). Unlike FEV1, RV in asthmatics (OR=1.008); RV and IRaw in COPD (OR=0.587 and OR=0.901, respectively), and FIF and TLC in restrictive patients (OR=1.041, and OR=0.962, respectively) proved the only sensitive predictors of the inspiratory airflow rate achievable at the different resistive regimens.

Conclusions: The intrinsic resistive regimen of DPIs can play a critical role. The patients' lung function profile also affects the extent of their inhalation airflow rate. Some specific lung function parameters (such as: FIF; RV; IRaw; TLC, but not FEV1) may be regarded as specific predictors in real-life. In order to optimize the DPI choice, further to the device's technology, also the current patients' lung function should be properly investigated and carefully assessed.

背景:dpi的性能取决于几个生理(患者依赖)和技术(设备依赖)因素。吸气气流速率是系统中产生和运行的唯一的动力,用于诱导所需的压降和引起通过装置分解粉末所需的阻力诱导湍流。本研究旨在探讨在最常见的呼吸系统疾病中,通过dpi模拟器模拟不同的内在阻力方案(低、中、高阻力)吸入时可达到的吸气气流速率是否以及在多大程度上受到肺功能特殊变化的影响和/或可以通过任何特定的肺功能参数来预测。方法:在招募时连续取样的受试者中,采用in - check DIAL G16在低、中、高阻力方案下按随机顺序评估吸气气流速率。通过针对该疾病的多变量logistic回归模型,研究了达到预期吸入气流速率的概率的独立预测因子。结果:共纳入114例受试者(哮喘患者30例;COPD患者50例,限制性患者16例,正常人18例)。预期吸入气流率的平均值在两组间差异有统计学意义(p < 0.01, p < 0.01);COPD患者的RV和IRaw (OR分别为0.587和0.901),限制性患者的FIF和TLC (OR分别为1.041和0.962)是不同阻力方案下吸气气流率的唯一敏感预测指标。结论:内阻治疗方案在DPIs中起关键作用。患者的肺功能也影响其吸入气流速率的大小。一些特定的肺功能参数(如:FIF;房车;IRaw;在现实生活中,TLC(而非FEV1)可能被认为是具体的预测指标。为了优化DPI的选择,除了设备的技术外,还应该对当前患者的肺功能进行适当的调查和仔细的评估。
{"title":"The contribution of patients' lung function to the inspiratory airflow rate achievable through a DPIs' simulator reproducing different intrinsic resistance rates.","authors":"Roberto W Dal Negro,&nbsp;Paola Turco,&nbsp;Massimiliano Povero","doi":"10.4081/mrm.2021.752","DOIUrl":"https://doi.org/10.4081/mrm.2021.752","url":null,"abstract":"<p><strong>Background: </strong>The performance of DPIs depends on several physiological (patient-dependent) and technological (device-dependent) factors. The inspiratory airflow rate is the only active force generated and operating in the system for inducing the required pressure drop and eliciting the resistance-induced turbulence needed to disaggregate the powder through the device. The present study aimed to investigate in the most prevalent respiratory disorders whether and at what extent the inspiratory airflow rate achievable when inhaling through a DPIs' simulator reproducing different intrinsic resistance regimens (low, mid, and high resistance) is affected by peculiar changes in lung function and/or can be predicted by any specific lung function parameter.</p><p><strong>Methods: </strong>The inspiratory airflow rate was assessed in randomized order by the In-Check DIAL G16 at low, mid, and high resistance regimens in a sample of consecutive subjects at recruitment. Independent predictors of the probability to achieve the expected inhalation airflow rate were investigated by means of a multivariate logistic regression model, specific to the disease.</p><p><strong>Results: </strong>A total of 114 subjects were recruited (asthmatics n=30; COPD n=50, restrictive patients n=16, and normal subjects n=18). The mean values of the expected inspiratory airflow rate achieved proved significantly different within the groups (p<0.0001), independently of sex and age. In asthmatics and in COPD patients, the mid-resistance regimen proved highly associated with the highest mean values of airflow rates obtained. Low- and high-resistance regimens were significantly less likely to consent to achieve the expected level of inspiratory airflow rate (OR<1 in all comparisons). Restrictive patients performed the lowest airflow rates at the low-resistance regimen (p<0.01). Unlike FEV<sup>1</sup>, RV in asthmatics (OR=1.008); RV and I<sub>Raw</sub> in COPD (OR=0.587 and OR=0.901, respectively), and FIF and TLC in restrictive patients (OR=1.041, and OR=0.962, respectively) proved the only sensitive predictors of the inspiratory airflow rate achievable at the different resistive regimens.</p><p><strong>Conclusions: </strong>The intrinsic resistive regimen of DPIs can play a critical role. The patients' lung function profile also affects the extent of their inhalation airflow rate. Some specific lung function parameters (such as: FIF; RV; I<sub>Raw</sub>; TLC, but not FEV<sub>1</sub>) may be regarded as specific predictors in real-life. In order to optimize the DPI choice, further to the device's technology, also the current patients' lung function should be properly investigated and carefully assessed.</p>","PeriodicalId":49031,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2021-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d3/03/mrm-16-1-752.PMC8077610.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38963988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Authors' response to the Letter to the Editor regarding: Preventive home therapy for symptomatic patients affected by COVID-19 and followed by teleconsultations. 作者对有关 "对受 COVID-19 影响的症状患者进行预防性家庭治疗并随后进行远程会诊 "的致编辑信的回复:对受 COVID-19 影响并随后接受远程会诊的无症状患者进行预防性家庭治疗。
IF 2.3 Pub Date : 2021-04-13 eCollection Date: 2021-01-15 DOI: 10.4081/mrm.2021.768
Gennaro D'Amato, Luca Acanfora, Lucrezia Delli Paoli, Maria D'Amato
{"title":"Authors' response to the Letter to the Editor regarding: Preventive home therapy for symptomatic patients affected by COVID-19 and followed by teleconsultations.","authors":"Gennaro D'Amato, Luca Acanfora, Lucrezia Delli Paoli, Maria D'Amato","doi":"10.4081/mrm.2021.768","DOIUrl":"10.4081/mrm.2021.768","url":null,"abstract":"","PeriodicalId":49031,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2021-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/60/f2/mrm-16-1-768.PMC8056324.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38848309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comments on "Preventive home therapy for symptomatic patients affected by COVID-19 and followed by teleconsultations" by D'Amato et al. D’amato等人对“COVID-19感染症状患者预防性家庭治疗并随后远程会诊”的评论
IF 2.3 Pub Date : 2021-04-08 eCollection Date: 2021-01-15 DOI: 10.4081/mrm.2021.757
Girolamo Adiletta, Stefano Baglioni, Germano Bettoncelli, Pierluigi Bracciale, Mario Cazzola, Enrico M Clini, Renato Cutrera, Franco D'Adduzio, Francesco de Blasio, Fausto Ferraro, Roberto Fumagalli, Cosimo Lequaglie, Maria Gabriella Matera, Fabio Numis, Paolo Palange, Stefano Picciolo, Alfredo Potena, Francesco Romano, Eugenio Sabato, Antonio Sacchetta, Mario Spatafora, Francesco Stefanelli, Carlo Zottola
Girolamo Adiletta,1 Stefano Baglioni,2 Germano Bettoncelli,3 Pierluigi Bracciale,4 Mario Cazzola,5 Enrico M. Clini,6 Renato Cutrera,7 Franco D’Adduzio,8 Francesco de Blasio,9,10 Fausto Ferraro,11 Roberto Fumagalli,12 Cosimo Lequaglie,13 Maria Gabriella Matera,14 Fabio Numis,15 Paolo Palange,16 Stefano Picciolo,17 Alfredo Potena,18 Francesco Romano,19 Eugenio Sabato,20 Antonio Sacchetta,21 Mario Spatafora,22 Francesco Stefanelli,23 Carlo Zottola24 1General Medicine, “Villa Malta” Hospital, Salerno 2Pneumology Department, Perugia Hospital 3General Practitioner, Brescia 4Pneumology Department, "Ninetto Melli" Hospital, San Pietro V.co (BR) 5Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome “Tor Vergata”, Rome 6Respiratory Disease Unit, University Hospital of Modena and University of Modena Reggio Emilia 7Respiratory Unit, Academic Department of Pediatrics, Bambino Gesù Children's Hospital, IRCCS, Rome 8UO Territorial Pneumology ASL BT, Barletta (BT) 9Respiratory Medicine and Pulmonary Rehabilitation Section, Clinic Center, Private Hospital, Naples 10Department of Medicine and Health Sciences 'V. Tiberio', University of Molise, Campobasso 11Department of Anesthetic, Surgical and Emergency Science, Second University of Naples 12Department of Medicine and Surgery, University of Milano Bicocca, Department of Anesthesia and Intensive Care, Ospedale Niguarda, Milan 13Department of Thoracic Surgery, IRCCS-CROB Centro Riferimento Oncologico Basilicata, Rionero in Vulture (PZ) 14Unit of Pharmacology, Department of Experimental Medicine, University of Campania “Luigi Vanvitelli”, Naples 15Emergency Department, Santa Maria delle Grazie Hospital, Naples 16Department of Clinical and Molecular Medicine, Division of Respiratory Diseases, Umberto I Hospital, Sapienza University, Rome 17Unit of Respiratory Medicine, Department of Medical Sciences, University Hospital of Messina 18General Medicine, Casa di Cura S.M. Maddalena Private Hospital, Occhiobello (RO) 19Respiratory Unit, Medical Center, Cosenza 20Pulmonology Ward, "A. Perrino" Hospital, Brindisi 21General Medicine, San Camillo Hospital, Treviso 22Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo (retired) 23Department of Pneumology, Monaldi Hospital, Naples 24Rehabilitation and Respiratory Section, INRCA-National Institute of Health and Sciences on Ageing, Cosenza, Italy
{"title":"Comments on \"Preventive home therapy for symptomatic patients affected by COVID-19 and followed by teleconsultations\" by D'Amato <i>et al.</i>","authors":"Girolamo Adiletta,&nbsp;Stefano Baglioni,&nbsp;Germano Bettoncelli,&nbsp;Pierluigi Bracciale,&nbsp;Mario Cazzola,&nbsp;Enrico M Clini,&nbsp;Renato Cutrera,&nbsp;Franco D'Adduzio,&nbsp;Francesco de Blasio,&nbsp;Fausto Ferraro,&nbsp;Roberto Fumagalli,&nbsp;Cosimo Lequaglie,&nbsp;Maria Gabriella Matera,&nbsp;Fabio Numis,&nbsp;Paolo Palange,&nbsp;Stefano Picciolo,&nbsp;Alfredo Potena,&nbsp;Francesco Romano,&nbsp;Eugenio Sabato,&nbsp;Antonio Sacchetta,&nbsp;Mario Spatafora,&nbsp;Francesco Stefanelli,&nbsp;Carlo Zottola","doi":"10.4081/mrm.2021.757","DOIUrl":"https://doi.org/10.4081/mrm.2021.757","url":null,"abstract":"Girolamo Adiletta,1 Stefano Baglioni,2 Germano Bettoncelli,3 Pierluigi Bracciale,4 Mario Cazzola,5 Enrico M. Clini,6 Renato Cutrera,7 Franco D’Adduzio,8 Francesco de Blasio,9,10 Fausto Ferraro,11 Roberto Fumagalli,12 Cosimo Lequaglie,13 Maria Gabriella Matera,14 Fabio Numis,15 Paolo Palange,16 Stefano Picciolo,17 Alfredo Potena,18 Francesco Romano,19 Eugenio Sabato,20 Antonio Sacchetta,21 Mario Spatafora,22 Francesco Stefanelli,23 Carlo Zottola24 1General Medicine, “Villa Malta” Hospital, Salerno 2Pneumology Department, Perugia Hospital 3General Practitioner, Brescia 4Pneumology Department, \"Ninetto Melli\" Hospital, San Pietro V.co (BR) 5Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome “Tor Vergata”, Rome 6Respiratory Disease Unit, University Hospital of Modena and University of Modena Reggio Emilia 7Respiratory Unit, Academic Department of Pediatrics, Bambino Gesù Children's Hospital, IRCCS, Rome 8UO Territorial Pneumology ASL BT, Barletta (BT) 9Respiratory Medicine and Pulmonary Rehabilitation Section, Clinic Center, Private Hospital, Naples 10Department of Medicine and Health Sciences 'V. Tiberio', University of Molise, Campobasso 11Department of Anesthetic, Surgical and Emergency Science, Second University of Naples 12Department of Medicine and Surgery, University of Milano Bicocca, Department of Anesthesia and Intensive Care, Ospedale Niguarda, Milan 13Department of Thoracic Surgery, IRCCS-CROB Centro Riferimento Oncologico Basilicata, Rionero in Vulture (PZ) 14Unit of Pharmacology, Department of Experimental Medicine, University of Campania “Luigi Vanvitelli”, Naples 15Emergency Department, Santa Maria delle Grazie Hospital, Naples 16Department of Clinical and Molecular Medicine, Division of Respiratory Diseases, Umberto I Hospital, Sapienza University, Rome 17Unit of Respiratory Medicine, Department of Medical Sciences, University Hospital of Messina 18General Medicine, Casa di Cura S.M. Maddalena Private Hospital, Occhiobello (RO) 19Respiratory Unit, Medical Center, Cosenza 20Pulmonology Ward, \"A. Perrino\" Hospital, Brindisi 21General Medicine, San Camillo Hospital, Treviso 22Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo (retired) 23Department of Pneumology, Monaldi Hospital, Naples 24Rehabilitation and Respiratory Section, INRCA-National Institute of Health and Sciences on Ageing, Cosenza, Italy","PeriodicalId":49031,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2021-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ef/f4/mrm-16-1-757.PMC8056322.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38848308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Rapid clinical evolution for COVID-19 translates into early hospital admission and unfavourable outcome: a preliminary report. 一份初步报告:COVID-19的快速临床演变导致早期住院和不利结果
IF 2.3 Pub Date : 2021-04-02 eCollection Date: 2021-01-15 DOI: 10.4081/mrm.2021.744
Markus Heim, Tobias Lahmer, Sebastian Rasch, Silja Kriescher, Wiebke Berg-Johnson, Kristina Fuest, Barbara Kapfer, Gerhard Schneider, Christoph D Spinner, Fabian Geisler, Johannes R Wießner, Kathrin Rothe, Susanne Feihl, Andreas Ranft

Background: A wide range of mortality rates has been reported in COVID-19 patients on the intensive care unit. We wanted to describe the clinical course and determine the mortality rate in our institution's intensive care units.

Methods: To this end, we performed a retrospective cohort study of 50 COVID-19 patients admitted to the ICU at a large German tertiary university hospital. Clinical features are reported with a focus on ICU interventions, such as mechanical ventilation, prone positioning and extracorporeal organ support. Outcome is presented using a 7-point ordinal scale on day 28 and 60 following ICU admission.

Results: The median age was 64 years, 78% were male. LDH and D-Dimers were elevated, and patients were low on Vitamin D. ARDS incidence was 75%, and 43/50 patients needed invasive ventilation. 22/50 patients intermittently needed prone positioning, and 7/50 required ECMO. The interval from onset of the first symptoms to admission to the hospital and to the ICU was shorter in non-survivors than in survivors. By day 60 after ICU admission, 52% of the patients had been discharged. 60-day mortality rate was 32%; 37% for ventilated patients, and 42% for those requiring both: ventilation and renal replacement therapy.

Conclusions: Early deterioration might be seen as a warning signal for unfavourable outcome. Lung-protective ventilation including prone positioning remain the mainstay of the treatment.

背景:重症监护病房COVID-19患者的死亡率有很大差异。我们想描述临床过程,并确定我们机构重症监护病房的死亡率。方法:为此,我们对德国某大型大学附属医院ICU收治的50例COVID-19患者进行了回顾性队列研究。临床特征报告重点ICU干预,如机械通气,俯卧位和体外器官支持。在ICU入院后的第28天和第60天,采用7分的顺序量表给出结果。结果:中位年龄64岁,男性占78%。LDH和d -二聚体升高,患者维生素d含量低,ARDS发生率为75%,43/50患者需要有创通气。22/50的患者需要间歇性俯卧位,7/50的患者需要ECMO。从出现首次症状到住院和进入ICU的时间间隔,非幸存者比幸存者短。入院后第60天,52%的患者已出院。60天死亡率为32%;37%为通气患者,42%为同时需要通气和肾脏替代治疗的患者。结论:早期恶化可能被视为不利结果的警告信号。包括俯卧位在内的肺保护性通气仍然是主要的治疗方法。
{"title":"Rapid clinical evolution for COVID-19 translates into early hospital admission and unfavourable outcome: a preliminary report.","authors":"Markus Heim, Tobias Lahmer, Sebastian Rasch, Silja Kriescher, Wiebke Berg-Johnson, Kristina Fuest, Barbara Kapfer, Gerhard Schneider, Christoph D Spinner, Fabian Geisler, Johannes R Wießner, Kathrin Rothe, Susanne Feihl, Andreas Ranft","doi":"10.4081/mrm.2021.744","DOIUrl":"10.4081/mrm.2021.744","url":null,"abstract":"<p><strong>Background: </strong>A wide range of mortality rates has been reported in COVID-19 patients on the intensive care unit. We wanted to describe the clinical course and determine the mortality rate in our institution's intensive care units.</p><p><strong>Methods: </strong>To this end, we performed a retrospective cohort study of 50 COVID-19 patients admitted to the ICU at a large German tertiary university hospital. Clinical features are reported with a focus on ICU interventions, such as mechanical ventilation, prone positioning and extracorporeal organ support. Outcome is presented using a 7-point ordinal scale on day 28 and 60 following ICU admission.</p><p><strong>Results: </strong>The median age was 64 years, 78% were male. LDH and D-Dimers were elevated, and patients were low on Vitamin D. ARDS incidence was 75%, and 43/50 patients needed invasive ventilation. 22/50 patients intermittently needed prone positioning, and 7/50 required ECMO. The interval from onset of the first symptoms to admission to the hospital and to the ICU was shorter in non-survivors than in survivors. By day 60 after ICU admission, 52% of the patients had been discharged. 60-day mortality rate was 32%; 37% for ventilated patients, and 42% for those requiring both: ventilation and renal replacement therapy.</p><p><strong>Conclusions: </strong>Early deterioration might be seen as a warning signal for unfavourable outcome. Lung-protective ventilation including prone positioning remain the mainstay of the treatment.</p>","PeriodicalId":49031,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2021-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/66/6a/mrm-16-1-744.PMC8056325.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38848307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Changes in spirometric parameters with position in asymptomatic Egyptian young males with central obesity. 无症状中心性肥胖的埃及年轻男性肺活量参数随体位的变化。
IF 2.3 Pub Date : 2021-04-01 eCollection Date: 2021-01-15 DOI: 10.4081/mrm.2021.745
Nermeen A Abd-Elaleem, Sherif A A Mohamed, Wael M Wagdy, Reham A Abd-Elaleem, Azza S Abdelhafeez, Hassan A Bayoumi

Background: Central obesity is a chronic condition that can contribute to impairments in lung functions. Body position is an important technique that effectively restores and increases lung functions. We aimed to address the possible changes in spirometric parameters in asymptomatic overweight individuals with central obesity with a change in posture from sitting to supine in comparison to normal weight non-obese ones.

Methods: Enrolled subjects were healthy Egyptian males, aged between 20-45 years old, asymptomatic and nonsmokers. They underwent spirometry. The following parameters were measured; forced expiratory volume in one second (FEV1), forced vital capacity (FVC), FEV1/FVC ratio, and forced expiratory flow (FEF)25-75%. They were classified into overweight with central obesity (n=40) and healthy control (n=40) groups based on their body mass index (BMI), weight-hip ratio (WHR), and waist circumference (WC). Spirometric parameters were compared between the 2 groups and in both setting and supine positions.

Results: The central obesity group showed significantly lower all spirometric parameters in comparison to the control one. All measured spirometric parameters had a significant reduction with supine position. There were negative correlations between both the WC and WHR and spirometric parameters.

Conclusion: In this study of young Egyptian males, individuals with central obesity had reduced spirometric parameters in comparison to healthy ones. Change in position from sitting to supine has significant effects on spirometric parameters in both healthy middle age males with normal weight and those with overweight and central obesity. These results could have important clinical implications.

背景:中心性肥胖是一种慢性疾病,可导致肺功能受损。体位是一个重要的技术,有效地恢复和增加肺功能。我们的目的是探讨无症状超重中心性肥胖患者与正常体重非肥胖者相比,从坐姿到仰卧姿势改变后肺活量测量参数可能发生的变化。方法:纳入的受试者为健康的埃及男性,年龄在20-45岁之间,无症状,不吸烟。他们接受了肺活量测定。测量了以下参数:1秒用力呼气量(FEV1)、用力肺活量(FVC)、FEV1/FVC比值、用力呼气流量(FEF)25 ~ 75%。根据体重指数(BMI)、体重臀围比(WHR)和腰围(WC)将他们分为超重合并中心性肥胖组(n=40)和健康对照组(n=40)。比较两组及平卧位和仰卧位的肺活量测定参数。结果:中心性肥胖组肺功能指标均明显低于对照组。所有测量的肺活量参数均随仰卧位而显著降低。WC、WHR与肺量计参数均呈负相关。结论:在这项对年轻埃及男性的研究中,与健康个体相比,中心性肥胖个体的肺活量测定参数降低。从坐位到仰卧位的改变对正常体重的健康中年男性和超重中心性肥胖男性的肺活量测定参数均有显著影响。这些结果可能具有重要的临床意义。
{"title":"Changes in spirometric parameters with position in asymptomatic Egyptian young males with central obesity.","authors":"Nermeen A Abd-Elaleem,&nbsp;Sherif A A Mohamed,&nbsp;Wael M Wagdy,&nbsp;Reham A Abd-Elaleem,&nbsp;Azza S Abdelhafeez,&nbsp;Hassan A Bayoumi","doi":"10.4081/mrm.2021.745","DOIUrl":"https://doi.org/10.4081/mrm.2021.745","url":null,"abstract":"<p><strong>Background: </strong>Central obesity is a chronic condition that can contribute to impairments in lung functions. Body position is an important technique that effectively restores and increases lung functions. We aimed to address the possible changes in spirometric parameters in asymptomatic overweight individuals with central obesity with a change in posture from sitting to supine in comparison to normal weight non-obese ones.</p><p><strong>Methods: </strong>Enrolled subjects were healthy Egyptian males, aged between 20-45 years old, asymptomatic and nonsmokers. They underwent spirometry. The following parameters were measured; forced expiratory volume in one second (FEV<sub>1</sub>), forced vital capacity (FVC), FEV<sub>1</sub>/FVC ratio, and forced expiratory flow (FEF)25-75%. They were classified into overweight with central obesity (n=40) and healthy control (n=40) groups based on their body mass index (BMI), weight-hip ratio (WHR), and waist circumference (WC). Spirometric parameters were compared between the 2 groups and in both setting and supine positions.</p><p><strong>Results: </strong>The central obesity group showed significantly lower all spirometric parameters in comparison to the control one. All measured spirometric parameters had a significant reduction with supine position. There were negative correlations between both the WC and WHR and spirometric parameters.</p><p><strong>Conclusion: </strong>In this study of young Egyptian males, individuals with central obesity had reduced spirometric parameters in comparison to healthy ones. Change in position from sitting to supine has significant effects on spirometric parameters in both healthy middle age males with normal weight and those with overweight and central obesity. These results could have important clinical implications.</p>","PeriodicalId":49031,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6c/10/mrm-16-1-745.PMC8054763.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38928435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Early responders within seven days of dupilumab treatment for severe asthma evaluated by patient-reported outcome: a pilot study. dupilumab治疗严重哮喘7天内的早期应答者通过患者报告的结果评估:一项试点研究
IF 2.3 Pub Date : 2021-03-17 eCollection Date: 2021-01-15 DOI: 10.4081/mrm.2021.736
Nozomi Tani, Nobutaka Kataoka, Yusuke Kunimatsu, Yusuke Tachibana, Takumi Sugimoto, Izumi Sato, Yuri Ogura, Kazuki Hirose, Takayuki Takeda

Background: The management of severe asthma-associated symptoms is essential since they are distressing to the affected patients, and also greatly impair their quality of life. Dupilumab, a monoclonal antibody, blocks interleukin (IL)-4 and IL-13 signaling, both of which are crucial in acquired and innate immunity pathways through fast signal transduction, leading to an early response to treatment. Although rapid improvement within 1-3 days after dupilumab treatment was observed in moderate-to-severe atopic dermatitis, an early response within 7 days of dupilumab treatment in severe asthma has not been reported.

Methods: Twelve consecutive patients with severe asthma who were newly treated with dupilumab between July 2019 and April 2020 were retrospectively investigated. We evaluated the early response (within 7 days) of patients with severe asthma receiving dupilumab therapy. Asthma control test (ACT) and the daily ACT, which was modified from the ACT to evaluate daily symptoms associated with asthma, were adopted as patient-reported outcomes (PROs) at week 8 and within 7 days, respectively. Patients were stratified into early responders (7 days), late responders (week 8), and non-responders without significant improvement in PROs. Descriptive statistics were adopted due to the limited number of patients.

Results: Four of these 12 patients were early responders, with the following baseline characteristics: body mass index, <25 kg/m2; without depression; baseline forced expiratory volume in 1 second, <1.50 L; and more than one exacerbation in 1 year. On the other hand, five were late responders, and 44.4% of the nine responders were early responders. The higher the eosinophilic count and/or FeNO did not show any relationship between the early responder and nonresponder.

Conclusions: The effect of dupilumab on severe asthma in patients with atopic features could be started earlier than 2 weeks, similar to atopic dermatitis. Daily ACT may be useful in monitoring the early efficacy of dupilumab in treating severe asthma.

背景:严重哮喘相关症状的处理是必要的,因为这些症状对受影响的患者来说是痛苦的,并且也极大地影响了他们的生活质量。Dupilumab是一种单克隆抗体,可阻断白细胞介素(IL)-4和IL-13信号传导,这两种信号通过快速信号转导在获得性和先天免疫途径中至关重要,从而导致对治疗的早期反应。虽然dupilumab治疗中重度特应性皮炎后1-3天内观察到快速改善,但dupilumab治疗严重哮喘后7天内的早期反应尚未报道。方法:回顾性分析2019年7月至2020年4月连续12例新接受杜匹单抗治疗的重症哮喘患者。我们评估了接受dupilumab治疗的严重哮喘患者的早期反应(7天内)。在第8周和第7天内,分别采用哮喘控制试验(ACT)和每日ACT作为患者报告的结果(PROs)。每日ACT由ACT改进,用于评估与哮喘相关的每日症状。患者被分为早期应答者(7天)、晚期应答者(第8周)和无应答者(无明显改善)。由于患者数量有限,采用描述性统计。结果:这12例患者中有4例是早期应答者,具有以下基线特征:体重指数,2;没有抑郁症;结论:与特应性皮炎相似,dupilumab治疗具有特应性特征的重症哮喘可早于2周开始。每日ACT可用于监测dupilumab治疗严重哮喘的早期疗效。
{"title":"Early responders within seven days of dupilumab treatment for severe asthma evaluated by patient-reported outcome: a pilot study.","authors":"Nozomi Tani,&nbsp;Nobutaka Kataoka,&nbsp;Yusuke Kunimatsu,&nbsp;Yusuke Tachibana,&nbsp;Takumi Sugimoto,&nbsp;Izumi Sato,&nbsp;Yuri Ogura,&nbsp;Kazuki Hirose,&nbsp;Takayuki Takeda","doi":"10.4081/mrm.2021.736","DOIUrl":"https://doi.org/10.4081/mrm.2021.736","url":null,"abstract":"<p><strong>Background: </strong>The management of severe asthma-associated symptoms is essential since they are distressing to the affected patients, and also greatly impair their quality of life. Dupilumab, a monoclonal antibody, blocks interleukin (IL)-4 and IL-13 signaling, both of which are crucial in acquired and innate immunity pathways through fast signal transduction, leading to an early response to treatment. Although rapid improvement within 1-3 days after dupilumab treatment was observed in moderate-to-severe atopic dermatitis, an early response within 7 days of dupilumab treatment in severe asthma has not been reported.</p><p><strong>Methods: </strong>Twelve consecutive patients with severe asthma who were newly treated with dupilumab between July 2019 and April 2020 were retrospectively investigated. We evaluated the early response (within 7 days) of patients with severe asthma receiving dupilumab therapy. Asthma control test (ACT) and the daily ACT, which was modified from the ACT to evaluate daily symptoms associated with asthma, were adopted as patient-reported outcomes (PROs) at week 8 and within 7 days, respectively. Patients were stratified into early responders (7 days), late responders (week 8), and non-responders without significant improvement in PROs. Descriptive statistics were adopted due to the limited number of patients.</p><p><strong>Results: </strong>Four of these 12 patients were early responders, with the following baseline characteristics: body mass index, <25 kg/m<sup>2</sup>; without depression; baseline forced expiratory volume in 1 second, <1.50 L; and more than one exacerbation in 1 year. On the other hand, five were late responders, and 44.4% of the nine responders were early responders. The higher the eosinophilic count and/or FeNO did not show any relationship between the early responder and nonresponder.</p><p><strong>Conclusions: </strong>The effect of dupilumab on severe asthma in patients with atopic features could be started earlier than 2 weeks, similar to atopic dermatitis. Daily ACT may be useful in monitoring the early efficacy of dupilumab in treating severe asthma.</p>","PeriodicalId":49031,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2021-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6e/fd/mrm-16-1-736.PMC7993019.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25574123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Modified PIRO (predisposition, insult, response, organ dysfunction) severity score as a predictor for mortality of children with pneumonia in Hasan Sadikin Hospital, Bandung, Indonesia. 改良的PIRO(易感、侮辱、反应、器官功能障碍)严重程度评分作为印度尼西亚万隆Hasan Sadikin医院肺炎患儿死亡率的预测因子
IF 2.3 Pub Date : 2021-03-10 eCollection Date: 2021-01-15 DOI: 10.4081/mrm.2021.735
Vebri Valentania, Dadang H Somasetia, Dany Hilmanto, Djatnika Setiabudi, Heda Melinda N Nataprawira

Background: Clinical manifestations for pneumonia vary from mild to severe. The PIRO model (predisposition, insult, response, organ dysfunction) was used as scoring system to determine severity of sepsis and pneumonia in adult patients. The PIRO model was modified for sorting the severity of pneumonia in children and predicting its risk of mortality.

Methods: An ambispective cohort study of pneumonia patients aged 1 month to ≤ 18 years admitted over the period from May to September 2020. Data were collected from history, physical examination, laboratory examination, and chest radiography. Based on bivariate analysis (p<0.05 and relative risk (RR) with 95% confidence interval), variables of each PIRO component that were significant for mortality were assigned a value of 1. The cut-off score for predictor of mortality was calculated using the receiver operating characteristics (ROC) curve and the scores were stratified into three degrees of risk based on interquartile range, score ≤Q1 was categorized as low risk; Q1-Q3 was categorized as moderate risk; and score >Q3 was categorized as high risk.

Results: Out of the 80 subjects enrolled, 6 months-5 years was the largest age group (56.3%). The observed mortality was 15/80 (18.8%). The modified PIRO severity score was compiled from significant variables of predisposition (malnutrition), insult (chest radiograph), response (hypoxemia, hypotension, CRP >0.5 mg/dL, PCT >0.5 ng/dL) and organ dysfunction, with range of score 0-7. Score >3 was categorized as a cut-off point score for predictor of mortality with AUC 0.919 (95% CI 0.836-0.968), sensitivity of 80%, and specificity of 84.62%. Subjects with score >3 have RR of 10.544 compared to those with score ≤3. The stratification of score level was low (≤2), moderate (3-4), and high (5-7). The mortality levels were 0%, 46.7%, and 53.3%, respectively.

Conclusions: Modified PIRO severity score can be used as a sorting tool and predictor of mortality risk in children with pneumonia. This score can also be used to select candidates for intensive care, especially in health facilities with limited intensive care capacity.

背景:肺炎的临床表现从轻到重不等。采用PIRO模型(易感、损伤、反应、器官功能障碍)作为评分系统来确定成人患者脓毒症和肺炎的严重程度。对PIRO模型进行了修改,以便对儿童肺炎的严重程度进行分类并预测其死亡风险。方法:对2020年5月至9月住院的1个月至≤18岁的肺炎患者进行双视角队列研究。资料收集自病史、体格检查、实验室检查和胸片。基于双变量分析(pQ3)被归类为高风险。结果:在入组的80名受试者中,6个月至5岁是最大的年龄组(56.3%)。观察死亡率为15/80(18.8%)。修改后的PIRO严重程度评分是根据易感因素(营养不良)、损伤(胸片)、反应(低氧血症、低血压、CRP >0.5 mg/dL、PCT >0.5 ng/dL)和器官功能障碍等显著变量编制的,评分范围为0-7分。评分>3分作为死亡预测指标的截止点评分,AUC为0.919 (95% CI 0.836-0.968),敏感性为80%,特异性为84.62%。得分>3的受试者与得分≤3的受试者相比,RR为10.544。评分水平分层为低(≤2)、中(3-4)、高(5-7)。死亡率分别为0%、46.7%和53.3%。结论:改良的PIRO严重程度评分可作为肺炎患儿死亡风险的分类工具和预测因子。该评分也可用于选择重症监护候选人,特别是在重症监护能力有限的卫生设施中。
{"title":"Modified PIRO (predisposition, insult, response, organ dysfunction) severity score as a predictor for mortality of children with pneumonia in Hasan Sadikin Hospital, Bandung, Indonesia.","authors":"Vebri Valentania,&nbsp;Dadang H Somasetia,&nbsp;Dany Hilmanto,&nbsp;Djatnika Setiabudi,&nbsp;Heda Melinda N Nataprawira","doi":"10.4081/mrm.2021.735","DOIUrl":"https://doi.org/10.4081/mrm.2021.735","url":null,"abstract":"<p><strong>Background: </strong>Clinical manifestations for pneumonia vary from mild to severe. The PIRO model (predisposition, insult, response, organ dysfunction) was used as scoring system to determine severity of sepsis and pneumonia in adult patients. The PIRO model was modified for sorting the severity of pneumonia in children and predicting its risk of mortality.</p><p><strong>Methods: </strong>An ambispective cohort study of pneumonia patients aged 1 month to ≤ 18 years admitted over the period from May to September 2020. Data were collected from history, physical examination, laboratory examination, and chest radiography. Based on bivariate analysis (p<0.05 and relative risk (RR) with 95% confidence interval), variables of each PIRO component that were significant for mortality were assigned a value of 1. The cut-off score for predictor of mortality was calculated using the receiver operating characteristics (ROC) curve and the scores were stratified into three degrees of risk based on interquartile range, score ≤Q1 was categorized as low risk; Q1-Q3 was categorized as moderate risk; and score >Q3 was categorized as high risk.</p><p><strong>Results: </strong>Out of the 80 subjects enrolled, 6 months-5 years was the largest age group (56.3%). The observed mortality was 15/80 (18.8%). The modified PIRO severity score was compiled from significant variables of predisposition (malnutrition), insult (chest radiograph), response (hypoxemia, hypotension, CRP >0.5 mg/dL, PCT >0.5 ng/dL) and organ dysfunction, with range of score 0-7. Score >3 was categorized as a cut-off point score for predictor of mortality with AUC 0.919 (95% CI 0.836-0.968), sensitivity of 80%, and specificity of 84.62%. Subjects with score >3 have RR of 10.544 compared to those with score ≤3. The stratification of score level was low (≤2), moderate (3-4), and high (5-7). The mortality levels were 0%, 46.7%, and 53.3%, respectively.</p><p><strong>Conclusions: </strong>Modified PIRO severity score can be used as a sorting tool and predictor of mortality risk in children with pneumonia. This score can also be used to select candidates for intensive care, especially in health facilities with limited intensive care capacity.</p>","PeriodicalId":49031,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2021-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/73/a9/mrm-16-1-735.PMC7967494.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25501094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Cardiopulmonary exercise pattern in patients with persistent dyspnoea after recovery from COVID-19. COVID-19康复后持续性呼吸困难患者的心肺运动模式
IF 2.3 Pub Date : 2021-01-25 eCollection Date: 2021-01-15 DOI: 10.4081/mrm.2021.732
Arno Mohr, Laura Dannerbeck, Tobias J Lange, Michael Pfeifer, Stefan Blaas, Bernd Salzberger, Florian Hitzenbichler, Myriam Koch
Cause and mechanisms of persistent dyspnoea after recovery from COVID-19 are not well described. The objective is to describe causal factors for persistent dyspnoea in patients after COVID-19. We examined patients reporting dyspnoea after recovery from COVID-19 by cardiopulmonary exercise testing. After exclusion of patients with pre-existing lung diseases, ten patients (mean age 50±13.1 years) were retrospectively analysed between May 14th and September 15th, 2020. On chest computed tomography, five patients showed residual ground glass opacities, and one patient showed streaky residua. A slight reduction of the mean diffusion capacity of the lung for carbon monoxide was noted in the cohort. Mean peak oxygen uptake was reduced with 1512±232 ml/min (72.7% predicted), while mean peak work rate was preserved with 131±29 W (92.4% predicted). Mean alveolar-arterial oxygen gradient (AaDO2) at peak exercise was 25.6±11.8 mmHg. Mean value of lactate post exercise was 5.6±1.8 mmol/l. A gap between peak work rate in (92.4% predicted) to peak oxygen uptake (72.3% pred.) was detected in our study cohort. Mean value of lactate post exercise was high in our study population and even higher (n.s.) compared to the subgroup of patients with reduced peak oxygen uptake and other obvious reason for limitation. Both observations support the hypothesis of anaerobic metabolism. The main reason for dyspnoea may therefore be muscular.
COVID-19康复后持续呼吸困难的原因和机制尚未得到很好的描述。目的是描述COVID-19患者持续呼吸困难的原因。我们通过心肺运动测试对COVID-19康复后报告呼吸困难的患者进行了检查。在排除已有肺部疾病的患者后,对2020年5月14日至9月15日期间的10例患者(平均年龄50±13.1岁)进行回顾性分析。胸部计算机断层扫描,5例患者显示残留磨玻璃影,1例患者显示条状残留。在队列中注意到一氧化碳的平均肺扩散能力略有降低。平均峰值摄氧量降低1512±232 ml/min(预测值72.7%),而平均峰值工作速率保持在131±29 W(预测值92.4%)。运动峰值时平均肺泡-动脉氧梯度(AaDO2)为25.6±11.8 mmHg。运动后乳酸均值为5.6±1.8 mmol/l。在我们的研究队列中发现峰值工作率(预测值为92.4%)与峰值摄氧量(预测值为72.3%)之间存在差距。在我们的研究人群中,运动后乳酸的平均值很高,甚至高于峰值摄氧量降低和其他明显限制原因的患者亚组(n.s.)。这两个观察结果都支持无氧代谢假说。因此,呼吸困难的主要原因可能是肌肉。
{"title":"Cardiopulmonary exercise pattern in patients with persistent dyspnoea after recovery from COVID-19.","authors":"Arno Mohr,&nbsp;Laura Dannerbeck,&nbsp;Tobias J Lange,&nbsp;Michael Pfeifer,&nbsp;Stefan Blaas,&nbsp;Bernd Salzberger,&nbsp;Florian Hitzenbichler,&nbsp;Myriam Koch","doi":"10.4081/mrm.2021.732","DOIUrl":"https://doi.org/10.4081/mrm.2021.732","url":null,"abstract":"Cause and mechanisms of persistent dyspnoea after recovery from COVID-19 are not well described. The objective is to describe causal factors for persistent dyspnoea in patients after COVID-19. We examined patients reporting dyspnoea after recovery from COVID-19 by cardiopulmonary exercise testing. After exclusion of patients with pre-existing lung diseases, ten patients (mean age 50±13.1 years) were retrospectively analysed between May 14th and September 15th, 2020. On chest computed tomography, five patients showed residual ground glass opacities, and one patient showed streaky residua. A slight reduction of the mean diffusion capacity of the lung for carbon monoxide was noted in the cohort. Mean peak oxygen uptake was reduced with 1512±232 ml/min (72.7% predicted), while mean peak work rate was preserved with 131±29 W (92.4% predicted). Mean alveolar-arterial oxygen gradient (AaDO2) at peak exercise was 25.6±11.8 mmHg. Mean value of lactate post exercise was 5.6±1.8 mmol/l. A gap between peak work rate in (92.4% predicted) to peak oxygen uptake (72.3% pred.) was detected in our study cohort. Mean value of lactate post exercise was high in our study population and even higher (n.s.) compared to the subgroup of patients with reduced peak oxygen uptake and other obvious reason for limitation. Both observations support the hypothesis of anaerobic metabolism. The main reason for dyspnoea may therefore be muscular.","PeriodicalId":49031,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2021-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f3/34/mrm-16-1-732.PMC7893311.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25398652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 39
Feasibility, utility, and safety of transbronchial cryobiopsy for interstitial lung diseases in Japan. 日本经支气管冷冻活组织检查治疗间质性肺病的可行性、实用性和安全性。
IF 2.3 Pub Date : 2021-01-25 eCollection Date: 2021-01-15 DOI: 10.4081/mrm.2021.731
Takato Ikeda, Akira Nakao, Fumiyasu Igata, Yoshiaki Kinoshita, Hisako Kushima, Takemasa Matsumoto, Hiroshi Ishii, Kazuki Nabeshima, Masaki Fujita

Background: Transbronchial lung cryobiopsy (TBLC) is a new technique that enables larger tissue collection than can be obtained by conventional transbronchial lung biopsy. TBLC is becoming popular worldwide and is performed for diffuse lung disease and lung cancer. However, only a few reports of TBLC have been published in Japan. This study was performed to evaluate the efficacy and safety of TBLC at our hospital and compare these findings with past reports.

Methods: From April 2018 to January 2020, 38 patients who underwent TBLC for diffuse lung disease at our hospital were evaluated with respect to age, sex, biopsy site, biopsy size, diagnostic disease, and complications.

Results: The patients who underwent TBLC were 20 men and 18 women with an average age of 63.7 years. The average sample size was 5.7 mm, and the diagnostic rate was 65.7% (25/38). Grade ≥2 complications included bleeding (15.8%), pneumothorax (2.6%), and atrial fibrillation (2.6%).

Conclusions: TBLC was considered to be useful for the diagnosis of diffuse lung disease and could be safely performed.

背景:经支气管肺冷冻活检术(TBLC)是一种新技术,与传统的经支气管肺活检术相比,它能采集到更多的组织。经支气管肺冷冻活检术正在全球范围内流行,可用于弥漫性肺部疾病和肺癌的治疗。然而,日本仅发表了几篇关于 TBLC 的报道。本研究旨在评估我院 TBLC 的疗效和安全性,并将这些结果与过去的报告进行比较:从 2018 年 4 月至 2020 年 1 月,对在我院接受 TBLC 治疗的 38 例弥漫性肺部疾病患者的年龄、性别、活检部位、活检大小、诊断疾病和并发症进行了评估:接受 TBLC 检查的患者中,男性 20 人,女性 18 人,平均年龄 63.7 岁。平均样本大小为 5.7 毫米,诊断率为 65.7%(25/38)。≥2级并发症包括出血(15.8%)、气胸(2.6%)和心房颤动(2.6%):结论:TBLC被认为有助于诊断弥漫性肺部疾病,而且可以安全进行。
{"title":"Feasibility, utility, and safety of transbronchial cryobiopsy for interstitial lung diseases in Japan.","authors":"Takato Ikeda, Akira Nakao, Fumiyasu Igata, Yoshiaki Kinoshita, Hisako Kushima, Takemasa Matsumoto, Hiroshi Ishii, Kazuki Nabeshima, Masaki Fujita","doi":"10.4081/mrm.2021.731","DOIUrl":"10.4081/mrm.2021.731","url":null,"abstract":"<p><strong>Background: </strong>Transbronchial lung cryobiopsy (TBLC) is a new technique that enables larger tissue collection than can be obtained by conventional transbronchial lung biopsy. TBLC is becoming popular worldwide and is performed for diffuse lung disease and lung cancer. However, only a few reports of TBLC have been published in Japan. This study was performed to evaluate the efficacy and safety of TBLC at our hospital and compare these findings with past reports.</p><p><strong>Methods: </strong>From April 2018 to January 2020, 38 patients who underwent TBLC for diffuse lung disease at our hospital were evaluated with respect to age, sex, biopsy site, biopsy size, diagnostic disease, and complications.</p><p><strong>Results: </strong>The patients who underwent TBLC were 20 men and 18 women with an average age of 63.7 years. The average sample size was 5.7 mm, and the diagnostic rate was 65.7% (25/38). Grade ≥2 complications included bleeding (15.8%), pneumothorax (2.6%), and atrial fibrillation (2.6%).</p><p><strong>Conclusions: </strong>TBLC was considered to be useful for the diagnosis of diffuse lung disease and could be safely performed.</p>","PeriodicalId":49031,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2021-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9b/dd/mrm-16-1-731.PMC7941050.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25468588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Multidisciplinary Respiratory Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1